Cytek Biosciences (CTKB) vs Harvard Bioscience (HBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Harvard Bioscience (HBIO) has outperformed Cytek Biosciences (CTKB) over the past year, gaining 37.5% versus a gain of 4.1%. Over five years, CTKB leads with a -67.8% price change compared with -87.4% for HBIO. Cytek Biosciences is the larger company by market cap ($800.4 million vs $39.6 million), about 20.2 times the size.
On valuation, Harvard Bioscience trades at a lower forward P/E (16.3x vs 87.4x for Cytek Biosciences). Cytek Biosciences converts more of its revenue into profit, with a net margin of -33.0% versus -65.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTKB | HBIO |
|---|---|---|
| Share price | $6.12 | $8.66 |
| Market cap | $800.40M | $39.60M |
| 1-day change | -3.16% | -0.23% |
| YTD return | +21.19% | +29.25% |
| 1-year return | +4.08% | +37.46% |
| 5-year return | -67.82% | -87.45% |
| Forward P/E | 87.43 | 16.34 |
| EPS (TTM) | $-0.63 | $-2.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $201.49M | $86.55M |
| Revenue growth (YoY) | +0.52% | -8.06% |
| Net income (latest FY) | $-66.54M | $-56.70M |
| Gross margin | 51.84% | 57.67% |
| Operating margin | -20.04% | -56.13% |
| Net margin | -33.02% | -65.51% |
| 52-week high | $6.39 | $10.20 |
| 52-week low | $3.31 | $4.00 |
| Distance from 52-week high | -4.15% | -15.10% |
| Analyst consensus | buy | none |
| Avg. price target upside | +6.21% | -13.39% |
| Average volume | 1.31M | 21.82K |
| Shares outstanding | 130.78M | 4.57M |
| Employees | 703 | 316 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cytek Biosciences is about 20.2 times larger than Harvard Bioscience by market value ($800.40M vs $39.60M).
- HBIO has outperformed CTKB by 33.4 percentage points over the past year.
- Cytek Biosciences is more profitable, keeping -33.0 cents of every revenue dollar as net income versus -65.5 cents for Harvard Bioscience.
- Cytek Biosciences grew revenue faster in its latest fiscal year (+0.52% vs -8.06%).
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 703 employees
About Harvard Bioscience
HBIO stock →Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 316 employees
CTKB vs HBIO FAQ
Which is bigger, Cytek Biosciences or Harvard Bioscience?
Cytek Biosciences (CTKB) is larger, with a market capitalization of $800.40M compared with $39.60M for Harvard Bioscience (HBIO).
Which stock has performed better over the past year, CTKB or HBIO?
HBIO returned +37.46% over the past 12 months, compared with +4.08% for CTKB (price return, excluding dividends). Past performance does not predict future results.
Are Cytek Biosciences and Harvard Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.